Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Lima | Healthcare | Pharmaceuticals | PEN 2.76T | 69.9x | 0.7 | PEN 3,242.79 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Lima | Healthcare | Pharmaceuticals | PEN 1.42T | 17.3x | -0.42 | PEN 599.01 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Lima | Healthcare | Pharmaceuticals | PEN 1.15T | 72.2x | -5.95 | PEN 705.59 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Lima | Healthcare | Pharmaceuticals | PEN 738.78B | 11.6x | 0 | PEN 302.49 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Lima | Healthcare | Pharmaceuticals | PEN 557.59B | 36.4x | -0.92 | PEN 986.43 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Lima | Healthcare | Pharmaceuticals | PEN 490.12B | 277.8x | -2.97 | PEN 410.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Lima | Healthcare | Pharmaceuticals | PEN 475.56B | 15.8x | 0.06 | PEN 82.92 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Lima | Healthcare | Pharmaceuticals | PEN 376.73B | -11.2x | 0.05 | PEN 185.22 | -9.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |